|
US10048271B2
(en)
|
2012-12-11 |
2018-08-14 |
Albert Einstein College Of Medicine, Inc. |
Methods for high throughput receptor:ligand identification
|
|
GB2538666A
(en)
*
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
AU2015301936B2
(en)
|
2014-08-11 |
2019-03-07 |
Delinia, Inc. |
Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN109071623B
(zh)
*
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
CA3019005A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CA3044416A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CA3054955A1
(en)
|
2017-03-15 |
2018-09-20 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
WO2018181638A1
(ja)
*
|
2017-03-29 |
2018-10-04 |
国立大学法人宮崎大学 |
長時間作用型アドレノメデュリン誘導体
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
RU2020120145A
(ru)
|
2017-11-21 |
2021-12-22 |
Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити |
Частичные агонисты интерлейкина-2
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
CA3083941A1
(en)
*
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Il-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
TW201930345A
(zh)
|
2017-12-27 |
2019-08-01 |
日商協和醱酵麒麟有限公司 |
Il-2改型體
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
US12226481B2
(en)
|
2018-01-24 |
2025-02-18 |
Beijing Percans Oncology Co., Ltd. |
Cytokine fusion proteins
|
|
WO2019158764A1
(en)
|
2018-02-16 |
2019-08-22 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
BR112020018709A2
(pt)
|
2018-03-28 |
2021-01-05 |
Bristol-Myers Squibb Company |
Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
JP7637415B2
(ja)
|
2018-06-22 |
2025-02-28 |
キュージーン インコーポレイテッド |
インターロイキン－２バリアントおよびその使用方法
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
CN112534052B
(zh)
|
2018-07-25 |
2024-09-20 |
奥美药业有限公司 |
全新il-21前药及使用方法
|
|
JP7289158B2
(ja)
|
2018-08-06 |
2023-06-09 |
メディカイン、インコーポレイテッド |
Ｉｌ－２受容体結合化合物
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
CA3123471A1
(en)
*
|
2018-12-21 |
2020-06-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Human interleukin-2 variant or derivative thereof
|
|
EP3917962A1
(en)
|
2019-02-01 |
2021-12-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
|
EP3924389A4
(en)
|
2019-02-15 |
2023-06-14 |
Integral Molecular, Inc. |
CLAUDIN-6 ANTIBODIES AND THEIR USES
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
WO2021021606A1
(en)
|
2019-07-26 |
2021-02-04 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
|
CN114222764B
(zh)
*
|
2019-08-12 |
2025-03-11 |
奥美药业有限公司 |
可优先结合IL-2Rα的IL-2融合蛋白
|
|
JP7427286B2
(ja)
|
2019-11-05 |
2024-02-05 |
メディカイン、インコーポレイテッド |
ＩＬ－２ＲβγＣ結合化合物
|
|
EP4055036A4
(en)
|
2019-11-05 |
2024-02-28 |
Medikine, Inc. |
DUAL IL-2R AND IL-7R BINDING CONNECTIONS
|
|
EP4073094A1
(en)
*
|
2019-12-12 |
2022-10-19 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
IL293978A
(en)
*
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
MX2022008771A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Metodos y composiciones de muteinas de il2 sesgadas.
|
|
TW202417475A
(zh)
|
2020-02-03 |
2024-05-01 |
美商麥地金公司 |
IL-7Rα結合化合物
|
|
BR112022015002A2
(pt)
|
2020-02-03 |
2022-12-06 |
Medikine Inc |
Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
EP4149534A4
(en)
|
2020-05-12 |
2024-09-04 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
|
|
CA3177843A1
(en)
|
2020-05-13 |
2021-11-18 |
John Thomas MULLIGAN |
Compositions of protein complexes and methods of use thereof
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
WO2022087458A1
(en)
|
2020-10-23 |
2022-04-28 |
Asher Biotherapeutics, Inc. |
Fusions with cd8 antigen binding molecules for modulating immune cell function
|
|
AU2021369823A1
(en)
|
2020-10-29 |
2023-06-01 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
WO2022100684A1
(zh)
|
2020-11-13 |
2022-05-19 |
江苏恒瑞医药股份有限公司 |
一种包含人白细胞介素2变体或其衍生物的药物组合物及其用途
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
JP2024514577A
(ja)
|
2021-04-09 |
2024-04-02 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
免疫寛容を増強するために高親和性ｉｌ－２受容体アゴニストと組み合わせて免疫抑制剤を含む合成ナノキャリア
|
|
CA3233644A1
(en)
|
2021-10-06 |
2023-04-13 |
David Klatzmann |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
|
US20230263906A1
(en)
|
2022-01-10 |
2023-08-24 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20230322884A1
(en)
|
2022-03-09 |
2023-10-12 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
US20230372535A1
(en)
|
2022-03-25 |
2023-11-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
WO2023196566A1
(en)
|
2022-04-08 |
2023-10-12 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260A
(zh)
*
|
2022-06-13 |
2022-11-11 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
WO2024056154A1
(en)
|
2022-09-12 |
2024-03-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin-2 for use in treating autism spectrum disorder
|
|
WO2024118771A1
(en)
|
2022-11-30 |
2024-06-06 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
CN120529914A
(zh)
|
2023-01-09 |
2025-08-22 |
奥德赛治疗股份有限公司 |
抗tnfr2抗原结合蛋白及其用途
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|